Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal)

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults because Takeda did not provide an evidence submission. 

Last reviewed: 14 August 2019

Next review: We will review this decision if the company decides to make a submission.

This technology appraisal guidance is now being reviewed as brentuximab vedotin for untreated advanced Hodgkin lymphoma [ID6334].

Guidance development process

How we develop NICE technology appraisal guidance